The 2023 ACR / EULAR Antiphospholipid ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
Titre :
The 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria
Auteur(s) :
Barbhaiya, Medha [Auteur]
Zuily, Stephane [Auteur]
Naden, Ray [Auteur]
Hendry, Alison [Auteur]
Manneville, Florian [Auteur]
Amigo, Mary‐carmen [Auteur]
Amoura, Zahir [Auteur]
Andrade, Danieli [Auteur]
Andreoli, Laura [Auteur]
Artim-Esen, Bahar [Auteur]
Atsumi, Tatsuya [Auteur]
Avcin, Tadej [Auteur]
Belmont, H. Michael [Auteur]
Bertolaccini, Maria Laura [Auteur]
Branch, D. Ware [Auteur]
Carvalheiras, Graziela [Auteur]
Casini, Alessandro [Auteur]
Cervera, Ricard [Auteur]
Cohen, Hannah [Auteur]
Costedoat-Chalumeau, Nathalie [Auteur]
Crowther, Mark [Auteur]
de Jesus, Guilherme [Auteur]
Delluc, Aurelien [Auteur]
Desai, Sheetal [Auteur]
de Sancho, Maria [Auteur]
Devreese, Katrien [Auteur]
Diz-Kucukkaya, Reyhan [Auteur]
Duarte-Garcia, Ali [Auteur]
Frances, Camille [Auteur]
Garcia, David [Auteur]
Gris, Jean‐christophe [Auteur]
Jordan, Natasha [Auteur]
Leaf, Rebecca [Auteur]
Kello, Nina [Auteur]
Knight, Jason [Auteur]
Laskin, Carl [Auteur]
Lee, Alfred [Auteur]
Legault, Kimberly [Auteur]
Levine, Steve [Auteur]
Levy, Roger [Auteur]
Limper, Maarten [Auteur]
Lockshin, Michael [Auteur]
Mayer-Pickel, Karoline [Auteur]
Musial, Jack [Auteur]
Meroni, Pier Luigi [Auteur]
Orsolini, Giovanni [Auteur]
Ortel, Thomas [Auteur]
Pengo, Vittorio [Auteur]
Petri, Michelle [Auteur]
Pons-Estel, Guillermo [Auteur]
Gomez-Puerta, Jose [Auteur]
Raimboug, Quentin [Auteur]
Roubey, Robert [Auteur]
Sanna, Giovanni [Auteur]
Seshan, Surya [Auteur]
Sciascia, Savino [Auteur]
Tektonidou, Maria [Auteur]
Tincani, Angela [Auteur]
Wahl, Denis [Auteur]
Willis, Rohan [Auteur]
Yelnik, Cecile [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Zuily, Catherine [Auteur]
Guillemin, Francis [Auteur]
Costenbader, Karen [Auteur]
Erkan, Doruk [Auteur]
Zuily, Stephane [Auteur]
Naden, Ray [Auteur]
Hendry, Alison [Auteur]
Manneville, Florian [Auteur]
Amigo, Mary‐carmen [Auteur]
Amoura, Zahir [Auteur]
Andrade, Danieli [Auteur]
Andreoli, Laura [Auteur]
Artim-Esen, Bahar [Auteur]
Atsumi, Tatsuya [Auteur]
Avcin, Tadej [Auteur]
Belmont, H. Michael [Auteur]
Bertolaccini, Maria Laura [Auteur]
Branch, D. Ware [Auteur]
Carvalheiras, Graziela [Auteur]
Casini, Alessandro [Auteur]
Cervera, Ricard [Auteur]
Cohen, Hannah [Auteur]
Costedoat-Chalumeau, Nathalie [Auteur]
Crowther, Mark [Auteur]
de Jesus, Guilherme [Auteur]
Delluc, Aurelien [Auteur]
Desai, Sheetal [Auteur]
de Sancho, Maria [Auteur]
Devreese, Katrien [Auteur]
Diz-Kucukkaya, Reyhan [Auteur]
Duarte-Garcia, Ali [Auteur]
Frances, Camille [Auteur]
Garcia, David [Auteur]
Gris, Jean‐christophe [Auteur]
Jordan, Natasha [Auteur]
Leaf, Rebecca [Auteur]
Kello, Nina [Auteur]
Knight, Jason [Auteur]
Laskin, Carl [Auteur]
Lee, Alfred [Auteur]
Legault, Kimberly [Auteur]
Levine, Steve [Auteur]
Levy, Roger [Auteur]
Limper, Maarten [Auteur]
Lockshin, Michael [Auteur]
Mayer-Pickel, Karoline [Auteur]
Musial, Jack [Auteur]
Meroni, Pier Luigi [Auteur]
Orsolini, Giovanni [Auteur]
Ortel, Thomas [Auteur]
Pengo, Vittorio [Auteur]
Petri, Michelle [Auteur]
Pons-Estel, Guillermo [Auteur]
Gomez-Puerta, Jose [Auteur]
Raimboug, Quentin [Auteur]
Roubey, Robert [Auteur]
Sanna, Giovanni [Auteur]
Seshan, Surya [Auteur]
Sciascia, Savino [Auteur]
Tektonidou, Maria [Auteur]
Tincani, Angela [Auteur]
Wahl, Denis [Auteur]
Willis, Rohan [Auteur]
Yelnik, Cecile [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Zuily, Catherine [Auteur]
Guillemin, Francis [Auteur]
Costenbader, Karen [Auteur]
Erkan, Doruk [Auteur]
Titre de la revue :
Arthritis & rheumatology
Pagination :
1687-1702
Éditeur :
Wiley
Date de publication :
2023-08-28
ISSN :
2326-5205
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. ...
Lire la suite >Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real‐world patient scenarios, and weighting via consensus‐based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators’ consensus as the gold standard. Results The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL‐associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid‐phase enzyme‐linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β 2 ‐glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versu s 86%, and a sensitivity of 84% versus 99%. Conclusion These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk‐stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.Lire moins >
Lire la suite >Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real‐world patient scenarios, and weighting via consensus‐based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators’ consensus as the gold standard. Results The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL‐associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid‐phase enzyme‐linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β 2 ‐glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versu s 86%, and a sensitivity of 84% versus 99%. Conclusion These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk‐stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Collections :
Source :